Visual Perceptual Learning for the Treatment of Visual Field Defect (VIVID2)
Primary Purpose
Visual Fields Hemianopsia, Hemianopsia, Homonymous
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Nunap Vision
Nunap Vision-C
Sponsored by
About this trial
This is an interventional treatment trial for Visual Fields Hemianopsia focused on measuring Visual field defect, visual perceptual learning, Humphrey visual field
Eligibility Criteria
Inclusion Criteria:
- Age 19-80 years
- Brain damage-induced visual field defect
- At least 6 months after brain lesion
- Minimum of 4 testing locations, where measured threshold ≤ 20dB
- Verified visual pathway damage using CT or MRI
- K-MMSE(Korean Mini Mental Status Examination) score ≥ 24
- Visual acuity equal or better than 20/40
- Able to use the investigational device
- Patient/legally authorized representative has signed the informed consent form
Exclusion Criteria:
- Unreliable Humphrey visual field test (any of fixation loss, false positive, false negative ≥ 20%)
- Complete hemianopsia with sensitivity of the whole hemifield ≤ 3 dB
- Epilepsy, photosensitivity, Parkinson's disease
- Bilateral visual field defect
- Hemispatial neglect
- Ophthalmologic disorder that may interfere the trial
- Inability to discontinue psychostimulants such as methylphenidate, modafinil, and amphetamine.
- Candidate for carotid endarterectomy or stenting
- Received ophthalmologic surgery within 3 months, except for the cataract surgery
- Pregnant or breast feeding
- Participating in other clinical trial
- Any other condition that, in the opinion of the investigator, precludes participation in the trial
Sites / Locations
- Seoul National University Bundang Hospital
- Asan Medical Center
- Chung-Ang University Hospital
- Konkuk University Hospital
- Samsung Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Nunap Vision
Nunap Vision-C
Arm Description
Nunap Vision , 5 days a week for 12 weeks
Nunap Vision-C, 5 days a week for 12 weeks
Outcomes
Primary Outcome Measures
Area of Humphrey visual field where sensitivity increased by equal or more than 6 dB relative to baseline
Improved regions have luminance sensitivity that increased by equal or more than 6 dB relative to baseline. The improved area ranges between 0 and 972 degree^2, of which larger area indicates better outcome.
Secondary Outcome Measures
Changes in Humphrey visual field mean deviation relative to baseline
Changes in mean deviation value of whole field or defect field compared with the baseline value. The change of mean deviation ranges between -35 to +35 dB, of which higher value indicates better outcome.
Changes in scores of NEI-VFQ-25(the National Eye Institute Visual Function Questionnaire 25) relative to baseline
Changes in each components of NEI-VFQ-25 scores relative to baseline. The change of scores ranges between -100 to 100, of which higher value indicates better outcome.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04102605
Brief Title
Visual Perceptual Learning for the Treatment of Visual Field Defect
Acronym
VIVID2
Official Title
Efficacy and Safety of Visual Perceptual Learning Using the Nunap Vision for Improvement of Visual Field Defect Caused by Brain Damage: Multi Center, Superiority Prove, Double-blind, Randomized, Confirmatory Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
October 17, 2019 (Actual)
Primary Completion Date
May 31, 2021 (Actual)
Study Completion Date
May 31, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nunaps Inc
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain damage. Half of participants will receive visual perceptual training using the Nunap Vision, while the other half will receive sham training using the Nunap Vision-C.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Visual Fields Hemianopsia, Hemianopsia, Homonymous
Keywords
Visual field defect, visual perceptual learning, Humphrey visual field
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nunap Vision
Arm Type
Experimental
Arm Description
Nunap Vision , 5 days a week for 12 weeks
Arm Title
Nunap Vision-C
Arm Type
Sham Comparator
Arm Description
Nunap Vision-C, 5 days a week for 12 weeks
Intervention Type
Device
Intervention Name(s)
Nunap Vision
Intervention Description
Participants receive visual perceptual training using the Nunap Vision software
Intervention Type
Device
Intervention Name(s)
Nunap Vision-C
Intervention Description
Participants receive sham training using the Nunap Vision-C software
Primary Outcome Measure Information:
Title
Area of Humphrey visual field where sensitivity increased by equal or more than 6 dB relative to baseline
Description
Improved regions have luminance sensitivity that increased by equal or more than 6 dB relative to baseline. The improved area ranges between 0 and 972 degree^2, of which larger area indicates better outcome.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Changes in Humphrey visual field mean deviation relative to baseline
Description
Changes in mean deviation value of whole field or defect field compared with the baseline value. The change of mean deviation ranges between -35 to +35 dB, of which higher value indicates better outcome.
Time Frame
12 weeks
Title
Changes in scores of NEI-VFQ-25(the National Eye Institute Visual Function Questionnaire 25) relative to baseline
Description
Changes in each components of NEI-VFQ-25 scores relative to baseline. The change of scores ranges between -100 to 100, of which higher value indicates better outcome.
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 19-80 years
Brain damage-induced visual field defect
At least 6 months after brain lesion
Minimum of 4 testing locations, where measured threshold ≤ 20dB
Verified visual pathway damage using CT or MRI
K-MMSE(Korean Mini Mental Status Examination) score ≥ 24
Visual acuity equal or better than 20/40
Able to use the investigational device
Patient/legally authorized representative has signed the informed consent form
Exclusion Criteria:
Unreliable Humphrey visual field test (any of fixation loss, false positive, false negative ≥ 20%)
Complete hemianopsia with sensitivity of the whole hemifield ≤ 3 dB
Epilepsy, photosensitivity, Parkinson's disease
Bilateral visual field defect
Hemispatial neglect
Ophthalmologic disorder that may interfere the trial
Inability to discontinue psychostimulants such as methylphenidate, modafinil, and amphetamine.
Candidate for carotid endarterectomy or stenting
Received ophthalmologic surgery within 3 months, except for the cataract surgery
Pregnant or breast feeding
Participating in other clinical trial
Any other condition that, in the opinion of the investigator, precludes participation in the trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sun U. Kwon, MD, PhD
Organizational Affiliation
Asan Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
Seoul National University Bundang Hospital
City
Seongnam
State/Province
Kyunggi-do
Country
Korea, Republic of
Facility Name
Asan Medical Center
City
Seoul
Country
Korea, Republic of
Facility Name
Chung-Ang University Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Konkuk University Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Visual Perceptual Learning for the Treatment of Visual Field Defect
We'll reach out to this number within 24 hrs